Navigation Links
Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support
Date:5/23/2013

JERUSALEM, May 23, 2013 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that its portfolio company, Cell Cure Neurosciences Ltd., received significant funding from the Israeli Ministry of Industry and Commerce, Office of the Chief Scientist (OCS) to support product development and advance clinical trials. Cell Cure's development budget totaling NIS 11.5 million (over $3 million USD) was approved for a grant of close to 50% financial support.

CEO of Hadasit Bio-Holdings, Ophir Shahaf , stated, "We are very pleased with the recent grant approvals. This substantial government support, particularly at a time of cut backs in government spending, is a vote of confidence and an expression of faith. The OCS conducted a rigorous evaluation of Cell Cure's scientific, managerial and potential. The financial support will fund up to 60% of certain aspects of the company's activities. Cell Cure is at the forefront of the regenerative medicine field with stem cell therapies posing as the promising future of medicine, attracting worldwide scientific reviews and substantial investments. Using the unique cell lines, directed differentiation process and controlled growth developed by the company, it can cause the cells to differentiate into various cells - cells that could literally replace the damaged cells in the human body in a wide range of diseases."

Mr. Shahaf continued, "In the coming year, we intend to initiate clinical trials in Israel and the U.S. to evaluate the safety and efficacy of Cell Cure's treatment for dry-AMD, OpRegen®. Age-related macular degeneration (AMD), is an eye disease that causes retinal degeneration and is the leading cause of blindness in the adult population of the western world, and yet there is no FDA approved treatment to date. Stem cell therapy may be a solution for a variety of diseases, but Cell Cure is focusing initially on AMD as it addresses an unmet medical need as well as a preferable regulatory route for this highly innovative treatment.  We believe that this external, non-dilutive funding to further advance our portfolio company's research and development as well as future collaborations with strategic partners in the pharmaceutical industry will continue to build value for the shareholders of Hadasit Bio-Holdings Ltd."

The OCS grant awarded to Cell Cure was previously announced by BioTime (NYSE MKT: BTX) on May 13, 2013.

For more information on Cell Cure please visit: www.cellcureneurosciences.com

For more information about Hadasit Bio-Holdings please visit: www.hbl.co.il

Investor Contact:
KCSA Strategic Communications
Phil Carlson / Josh Dver
212.896.1233 / 1239
pcarlson@kcsa.com / jdver@kcsa.com 


'/>"/>
SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hadasit Bio-Holdings Portfolio Companies Receive Funding to Support Clinical Trial Preparations and Obtain Regulatory Approvals in U.S. and Europe
2. Hadasit Bio-Holdings Flagship Portfolio Company Enlivex Awarded Orphan Drug Status for ApoCell Treatment by the FDA
3. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
4. Pernix Therapeutics Introduces Omeclamox-Pak®, First Product in Gastroenterology Portfolio
5. NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
6. Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
7. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
8. iBio Announces Important Expansion of its Intellectual Property Portfolio: Allowance of Patent for Anthrax Vaccines and Further Application of Modulator Platform
9. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
10. RoundTable Healthcare Partners Portfolio Company, Renaissance Acquisition Holdings, LLC Acquires DPT Laboratories
11. Kimberly-Clark Health Care Receives FDA Clearance For KIMGUARD ONE-STEP Sterilization Wrap Portfolio With One-Year Maintenance Of Package Integrity And Amsco V-PRO maX (Flexible Cycle)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... Mich. , July 13, 2017  Centurion Medical Products, a ... its DisImpactor ® fecal impaction removal device for hospice patient ... ... Patient pain management and ... for Hospice can help alleviate patient pain while preventing unneeded emergency ...
(Date:7/11/2017)... IRVINE, Calif. , July 11, 2017 Zymo Research Corp., ... new service that can quantify biological aging in a precise manner using ... Dr. Steve Horvath , a professor of human genetics and biostatistics ... Fielding School of Public Health , Zymo Research,s proprietary DNAge ™ ... loci. ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... development of oral drug delivery systems, announced today that ... to schedule an End-of-Phase II meeting with Oramed for ... insulin capsule ORMD-0801 in the treatment of type 2 ... endpoints by indicating a statistically significant lowering of glucose ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... July 26, 2017 , ... Evergreen Healthcare Partners is ... continued efforts to provide innovative offerings to their healthcare partners. These solutions will ... dynamic, high-performing teams to address healthcare IT’s biggest challenges. , “Adding Talent Management ...
(Date:7/26/2017)... ... ... may be hard to imagine that the basic necessities that developed countries take for ... developed countries consider rare or eradicated, like measles, are still a rite of passage ... segment of "Success Files", actor Rob Lowe will introduce a new segment that will ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... will host its 2017 Process Validation and Process Validation Statistics Conferences in ... to process validation lifecycle challenges faced by process validation professionals and statisticians ...
(Date:7/26/2017)... Newport Beach, CA 92660 (PRWEB) , ... ... ... of Data Loss Prevention for on-premises, off and in the cloud ; today ... intelligent detection and scientific algorithms within a simple to use control console for ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with Six ... schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing patients ... will bring more Six Month Smiles patients to their providers.” , Each month, over ...
Breaking Medicine News(10 mins):